睿智医药(300149) - 2023 Q2 - 季度财报(更新)

Company Overview This section provides an overview of the company's profile, key financial performance, shareholder structure, and control status Company Profile RZ Medicine Science and Technology Co., Ltd. (stock code: 300149) is a company listed on the Shenzhen Stock Exchange - The company is referred to as "RZ Medicine", with stock code 300149, listed on the Shenzhen Stock Exchange[1] Key Accounting Data and Financial Indicators In H1 2023, the company's operating revenue was 557 million yuan, a year-on-year decrease of 18.84%; net profit attributable to shareholders was a loss of 15.1 million yuan, a significant year-on-year decrease of 101.58% Key Financial Indicators for H1 2023 | Indicator | Current Period | Prior Year Period | Year-on-Year Change | | :--- | :--- | :--- | :--- | | Operating Revenue (Million Yuan) | 557.45 | 686.90 | -18.84% | | Net Profit Attributable to Shareholders (Million Yuan) | -15.10 | 956.58 | -101.58% | | Net Profit Attributable to Shareholders Excluding Non-recurring Gains and Losses (Million Yuan) | -22.20 | -34.99 | 36.56% | | Net Cash Flow from Operating Activities (Million Yuan) | 7.56 | 42.73 | -82.32% | | Basic Earnings Per Share (Yuan / Share) | -0.03 | 1.92 | -101.56% | | Total Assets (Billion Yuan) | 3.42 | 3.81 | -10.15% | - Net profit attributable to shareholders significantly decreased by 101.58% year-on-year, primarily due to substantial investment gains from the divestiture of the prebiotics business in H1 2022[5] Shareholder Information As of the end of the reporting period, the company had a total of 24,671 common shareholders, with the top three holding significant stakes - As of the end of the reporting period, the company had a total of 24,671 common shareholders[3] Top Three Shareholder Holdings | Shareholder Name | Shareholding Percentage | Number of Shares Held | | :--- | :--- | :--- | | Beihai Baben Venture Capital Co., Ltd. | 13.69% | 68,441,800 | | Hangzhou Cixuan Liangjia Investment Management Partnership (Limited Partnership) | 10.24% | 51,185,660 | | Shanghai Ruiyun Enterprise Management Center (Limited Partnership) | 6.88% | 34,380,629 | Controlling Shareholder and Actual Controller During the reporting period, there were no changes in the company's controlling shareholder or actual controller - The company's controlling shareholder and actual controller remained unchanged during the reporting period[4] Significant Matters and Operations Analysis This section analyzes the company's overall operating performance and the specific performance of its key business segments Overall Operating Performance In H1 2023, the company achieved operating revenue of 557 million yuan, a year-on-year decrease of 18.84%, primarily due to business divestitures - In H1 2023, operating revenue was 557 million yuan, a year-on-year decrease of 18.84%; net profit attributable to shareholders was -15.0957 million yuan, a year-on-year decrease of 101.58%[5] - The year-on-year revenue decline was primarily due to the company's divestiture of its small molecule CDMO and prebiotics businesses in H1 2022, leading to a different revenue composition compared to the prior year[5] Revenue Composition of Pharmaceutical R&D Services and Manufacturing Business (Unit: 10,000 Yuan) | Business Segment | H1 2023 | H1 2022 | Period-over-Period Change (%) | | :--- | :--- | :--- | :--- | | Total | 55,686.21 | 55,287.73 | 0.72% | | Chemistry Business | 17,093.05 | 16,589.98 | 3.03% | | Pharmacodynamics and Pharmacokinetics Business | 27,067.61 | 25,206.86 | 7.38% | | Large Molecule Business | 11,145.30 | 11,935.96 | -6.62% | Operating Performance by Business Segment During the reporting period, the company's three core business segments showed differentiated performance, with PD/PK as a growth engine, chemistry showing modest growth, and large molecule business experiencing a decline Chemistry Business Segment The Chemistry business generated revenue of 171 million yuan, a year-on-year increase of 3.03%, with the company actively deploying cutting-edge technologies and expanding service capabilities - The Chemistry business segment achieved operating revenue of 170.9305 million yuan, a year-on-year increase of 3.03%[6][8] - The company is continuously building new technology platforms for ADC Payload and Linker, PROTAC, Peptide-Drug Conjugates (PDC), and small nucleic acid research and development to enhance competitiveness[8] - Subsidiary Chengdu RZ Medicine was recognized as a national-level "Little Giant" enterprise, demonstrating the company's professional strength in heterocyclic small molecule synthesis[8] Pharmacodynamics and Pharmacokinetics Business Segment The Pharmacodynamics and Pharmacokinetics (PD/PK) business generated revenue of 271 million yuan, a year-on-year increase of 7.38%, driven by expansion of its large animal experimental platform - The Pharmacodynamics and Pharmacokinetics business segment achieved operating revenue of 270.6761 million yuan, a year-on-year increase of 7.38%[9] - To accommodate business growth, the company is actively expanding its Qidong large animal experimental platform by nearly 1,500 square meters to increase the number of cynomolgus monkeys and beagle dogs[9] Large Molecule Business Segment The Large Molecule business generated revenue of 111 million yuan, a year-on-year decrease of 6.62%, primarily due to the slowdown in the domestic biopharmaceutical industry - The Large Molecule business segment achieved operating revenue of 111.4530 million yuan, a year-on-year decrease of 6.62%[9] - The performance decline was mainly influenced by the slowdown in the domestic biopharmaceutical industry, leading to lower-than-expected order acquisition[9] - During the reporting period, the Zhangjiang Large Molecule CDMO service projects totaled 43 (28 preclinical, 15 clinical Phase I), and supported 2 projects in IND applications, 2 projects in obtaining NMPA clinical approval, and 1 project in obtaining FDA clinical approval[10]